Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine

Dean A Blumberg, Patricia C. Chatfield, James D. Cherry, Ricki G. Robinson, Kathleen Smith, Laura Mabie, H. James Holroyd, Leonard R. Baker, Frank E. Dudenhoeffer, Noelani Apau, Jill G. Hackell, Andrea Cawein

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 μg/dose), filamentous haemagglutinin (70 μg/dose), agglutinogens (1.4 μg/dose) and the 69 kDa protein (≈8.0 μg/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.

Original languageEnglish (US)
Pages (from-to)614-616
Number of pages3
Issue number9
StatePublished - 1992
Externally publishedYes


  • acellular vaccine
  • children
  • filamentous haemagglutinin
  • immunogenicity
  • Pertussis
  • reactogenicity

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)


Dive into the research topics of 'Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine'. Together they form a unique fingerprint.

Cite this